378 related articles for article (PubMed ID: 30019863)
1. Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol.
Asghari F; Haghnavaz N; Shanehbandi D; Khaze V; Baradaran B; Kazemi T
Adv Clin Exp Med; 2018 Jul; 27(7):941-945. PubMed ID: 30019863
[TBL] [Abstract][Full Text] [Related]
2. Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.
Tao WY; Liang XS; Liu Y; Wang CY; Pang D
Int J Biol Sci; 2015; 11(1):48-58. PubMed ID: 25552929
[TBL] [Abstract][Full Text] [Related]
3. HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines.
Haghnavaz N; Asghari F; Elieh Ali Komi D; Shanehbandi D; Baradaran B; Kazemi T
Artif Cells Nanomed Biotechnol; 2018 May; 46(3):518-523. PubMed ID: 28509576
[TBL] [Abstract][Full Text] [Related]
4. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
7. Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer.
Shekari N; Asghari F; Haghnavaz N; Shanehbandi D; Khaze V; Baradaran B; Kazemi T
Anticancer Agents Med Chem; 2019; 19(3):304-309. PubMed ID: 30543177
[TBL] [Abstract][Full Text] [Related]
8. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
Wang R; Zhang T; Yang Z; Jiang C; Seng J
J Cell Mol Med; 2018 Sep; 22(9):4068-4075. PubMed ID: 29971911
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.
Li Y; Zhang L; Dong Z; Xu H; Yan L; Wang W; Yang Q; Chen C
Pathol Res Pract; 2021 Apr; 220():153405. PubMed ID: 33756128
[TBL] [Abstract][Full Text] [Related]
11. c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell Line.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Tsumura H
PLoS One; 2015; 10(9):e0138560. PubMed ID: 26393798
[TBL] [Abstract][Full Text] [Related]
12. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.
Zhu M; Wang F; Mi H; Li L; Wang J; Han M; Gu Y
Cell Cycle; 2020 Dec; 19(23):3277-3288. PubMed ID: 33121324
[TBL] [Abstract][Full Text] [Related]
15. All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.
El Habre R; Aoun R; Tahtouh R; Hilal G
BMC Cancer; 2024 May; 24(1):615. PubMed ID: 38773429
[TBL] [Abstract][Full Text] [Related]
16. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
18. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel.
Wu H; Huang M; Lu M; Zhu W; Shu Y; Cao P; Liu P
Cancer Chemother Pharmacol; 2013 May; 71(5):1159-71. PubMed ID: 23423488
[TBL] [Abstract][Full Text] [Related]
19. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells.
Lv K; Liu L; Wang L; Yu J; Liu X; Cheng Y; Dong M; Teng R; Wu L; Fu P; Deng W; Hu W; Teng L
PLoS One; 2012; 7(7):e40008. PubMed ID: 22808086
[TBL] [Abstract][Full Text] [Related]
20. lncRNA NEAT1 promotes the Taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis.
Zhu L; Wang F; Fan W; Jin Z; Teng C; Zhang J
Acta Biochim Biophys Sin (Shanghai); 2021 Aug; 53(9):1198-1206. PubMed ID: 34327529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
